Respiri : Presentation at Innovate Health 2022 Conference

Investor presentation at Innovate Health 2022 Conference

ASX ANNOUNCEMENT 22 July 2022

onlymanagement, is pleased to announce that the Company's Managing Director Marjan Mikel is invited as a presenter at the Innovate Health 2022 Conference (the "Conference") to speak on the topic of "Care beyond the clinic replaying the innovation journey". The presentation is attached.

Respiri Limited (ASX:RSH)("Respiri" or the "Company"), an eHealth SaaS Company supporting respiratory health

The Conference will be held at Collins Square Events Centre, Melbourne on the 26th and 27th of July 2022 at 09 useam AEST. Marjan Mikel will be speaking on the above-mentioned topic on 27th July 2022 at 11:40am.

The registration to attend the Conference is as follows:

https://www.informa.com.au/event/conference/healthcare-nursing/innovate-health- conference/?utm_source=Office_use&utm_medium=PDF&utm_campaign=P18A06

- ENDS -
personal
For further information, investors and media please contact:
Mr Marjan Mikel	Mr Nicholas Smedley
CEO & Managing Director	Executive Chairman
Respiri Limited	Respiri Limited
P: [phone]	P: [phone]
E: [e-mail]	E: [e-mail]
™ wheezo is a trademark of Respiri Limited.

This ASX announcement dated 22 July 2022 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects Forwheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management

platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative

Respiri Limited │ ABN 98 009 234 173 │ Suite 1, Level 9, 432 St Kida Road, MELBOURE VIC 3004 │

Page | 1

wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo, follow the online link https://wheezo.comonlyForward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates, " "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology

useand in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate

personalregulatory authority.

For

Respiri Limited │ ABN 98 009 234 173 │ Suite 1, Level 9, 432 St Kida Road, MELBOURE VIC 3004 │

Page | 2

ersonal use only

Care Beyond the Clinic

RPM provides medically supervised self-management

Replaying the innovation journey

July 2022

Marjan Mikel (RESPIRI CEO)

ASX:RSH

Innovate Health 2022

Health systems worldwide are financially burdened by chronic disease

ersonal use only

1 Globally ~ 1 in 3 of adults suffer from multiple chronic conditions1

1. 3 in 5 global deaths are attributed to four major non-communicable diseases; cardiovascular disease, cancer, chronic lung diseases and diabetes2
2. Problems are amplified by ageing populations and the pandemic

References: 1. Hajat and Stein 2018, 2. Wang et al., 2016

Historically, Australian governments have been focused on:

ersonal use only

Abbreviations: PPHs, Potentially preventable hospitalisations

References: 1. AIHW (2019)Hospitals at a glance2017-18,accessed 20 July2022,2.How Often Do Australians Visit a Doctor? We Break GP Visits Down By

Demographics, accessed 20 July 2022, 3. ABS Health literacy, Australia 2008. accessed 2009

Prevention including public health advertising

Funded diagnosis and treatment

BUT provision of ongoing health management left to the patient…

AND this approach is not working as evidenced by the

Australian patient experience:

rates of PPHs	of patients with a
increased to	chronic condition

	60%3
						29%
		27.9%
	have low
	per 1,000	see a doctor
health literacy	population1	between 1-3

times per year2